scholarly journals Impact of factors affecting the residual tumor size diagnosed by MRI following neoadjuvant chemotherapy in comparison to pathology

2013 ◽  
Vol 109 (2) ◽  
pp. 158-167 ◽  
Author(s):  
Jeon-Hor Chen ◽  
Shadfar Bahri ◽  
Rita S. Mehta ◽  
Philip M. Carpenter ◽  
Christine E. McLaren ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Tumor Size ◽  
Residual Tumor ◽  
Factors Affecting ◽  
Residual Tumor Size

scholarly journals Dynamic Contrast-enhanced Breast MRI for Evaluating Residual Tumor Size after Neoadjuvant Chemotherapy

Radiology ◽  
2018 ◽  
Vol 289 (2) ◽  
pp. 327-334 ◽  
Author(s):  
Soo-Yeon Kim ◽  
Nariya Cho ◽  
In-Ae Park ◽  
Bo Ra Kwon ◽  
Sung Ui Shin ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Tumor Size ◽  
Breast Mri ◽  
Residual Tumor ◽  
Dynamic Contrast Enhanced ◽  
Residual Tumor Size ◽  
Contrast Enhanced

Breast MRI for Evaluating Residual Tumor Size Following Neoadjuvant Chemotherapy: Clinicopathologic Factors and MRI Imaging Features Affecting Its Accuracy

2021 ◽  
Vol 17 ◽  
Author(s):  
Jin Young Park ◽  
Young Seon Kim ◽  
Seung Eun Lee
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Tumor Size ◽  
Breast Imaging ◽  
Residual Tumor ◽  
Imaging Features ◽  
Her2 Positive ◽  
Residual Tumor Size ◽  
Mri Features ◽  
Er Positive ◽  
Size Discrepancy

Objectives: To investigate the accuracy of breast magnetic resonance imaging (MRI) for evaluating residual tumor size following neoadjuvant chemotherapy (NAC) and to identify clinicopathologic and MRI features affecting its accuracy. Materials and methods: We retrospectively assessed 109 women who underwent preoperative dynamic contrast-enhanced (DCE) MRI following NAC and subsequent surgery between April 2016 and August 2020. Preoperative MRI features, including Breast Imaging Reporting and Data System lexicon characteristics, size of residual enhancing lesion, tumor shrinkage pattern, and clinicopathologic features were investigated, and MRI and pathology findings were compared. Results: Residual tumor size on MRI showed high agreement with residual invasive tumor size on pathologic examination (ICC, 0.808, p<0.001). The residual tumor size measured by MRI and final pathologic size were concordant in 63/109 cases (57.8%), while MRI overestimated the size in 35/109 cases (32.1%). For estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative tumors, MRI tended to underestimate the residual tumor size compared with HER2-positive cancers (p=0.002) and triple-negative cancers (p=0.12). On MRI, tumors with concentric shrinkage patterns after NAC showed less size discrepancy with final pathologic tumor size than those with nonconcentric patterns (p=0.026). Conclusion: ER-positive/HER2-negative cancers are tended to underestimate the residual tumor size by MRI compared with other subtypes. Tumors with concentric shrinkage patterns after NAC showed less MRI/pathology size discrepancy.

scholarly journals MRI evaluation of residual tumor size after neoadjuvant endocrine therapy vs. neoadjuvant chemotherapy

2012 ◽  
Vol 81 (9) ◽  
pp. 2148-2153 ◽  
Author(s):  
Kazuna Takeda ◽  
Shotaro Kanao ◽  
Tomohisa Okada ◽  
Takayuki Ueno ◽  
Masakazu Toi ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Endocrine Therapy ◽  
Tumor Size ◽  
Residual Tumor ◽  
Neoadjuvant Endocrine Therapy ◽  
Residual Tumor Size ◽  
Mri Evaluation

ROLE OF SONOMAMMOGRAPHY IN MONITORING THE RESPONSE OF NEOADJUVANT CHEMOTHERAPY IN MALIGNANT BREAST MASSES

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Sherine George Moftah ◽  
Essam Mohamed Hafez ◽  
Walid Dahy Zidan
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Tumor Size ◽  
Locally Advanced ◽  
Residual Tumor ◽  
High Accuracy ◽  
Breast Ultrasound ◽  
Radiology Department ◽  
Duration Of Symptoms ◽  
Progressive Course

Abstract Background Breast cancer is a leading cause of death and disability between women, particularly young women, in low- and average -income countries (Porter, 2018). Neoadjuvant chemotherapy (NAC) is increasingly used in management patients with locally advanced breast cancer (LABC) (Mougalian et al., 2015). Mammography and breast ultrasound are the most widest diagnostic techniques used to evaluate primary tumor size and character at the time of diagnosis and monitoring the response to NAC (Kald et al., 2015). Aim of the work The purpose of this study is to assess and evaluate the role and the accuracy of Mammography and breast ultrasound modalities in monitoring the response of the breast cancer to the neoadjuvant chemotherapy. Patients and methods Twenty three patients presenting with pathologically proven malignant mass and conducted for neoadjuvant chemotherapy with age above 40 years-old. They were referred to the radiology department (mammography unit, Ultrasound unit and MRI unit) at El Salam oncology center, during the period between December 2018 to June 2019. Once a patient satisfied the inclusion and exclusion criteria for this study, an elaborate history was taken from all the patients which was followed by a thorough clinical evaluation, in which duration of symptoms, affected side, affected breast and family history. Patients were subjected to evaluation before starting neoadjunant chemotherapy by mammography, ultrasound and MRI as well as after finishing the neoadjuvant cycles which usually was ranging 3-4 cycles. Results Total of 23 patients with breast cancer were enrolled in this study. The patients were in the age group of 41-70 years with mean age of 54 years. Majority of patients had infiltrative ductal carcinoma IDC (16 cases -69.56% and the rest of cases were infiltrative lobular carcinoma (9 cases -39.13 %). After monitoring the response of the cases to neoadjuvant chemotherapy the results showed significant regressive course to the majority of cases ( 17 cases ) (73.91%) with the rest non respondent cases divided to cases with stationary ( 3 cases ) (13.04% ) and cases with progressive course ( 3 cases ) (13.04% ). The comparison between the results of Sonomammographic assessment of the breast lesions before and after the neoadjuvant chemotherapy cycles and also to MRI show close results. There were 5 cases that showed non-respondent (including stationary course and progressive course) in both Sonomammography and MRI and only one case that was respondent according to Sonomammography and non-respondent according to MRI breast (false +e). On the other hand there were 16 cases that had showed respondent fashion in both Sonomammography and MRI. Also there was one case that had showed non-respondent course according to Sonomammography and was respondent according to MRI results (false –ve). Sonomammography sensitivity was 94.12 % and specificity was 83.33% compared to MRI results, with high accuracy value reaching to 91.30 %. Conclusion The ability of mammography and breast ultrasound to accurately measure residual tumor size following neoadjuvant chemotherapy compared to Breast MRI measurement of the residual tumor demonstrated sensitivity of 94.12 % and specificity of 83.33% with high accuracy value reaching to 91.30 %. Even that the MRI is proved to be of high accuracy in detecting residual tumor, sonomammographic imaging isa cost-effective imaging modality than the MRI with sensitivity and specificity near to that of MRI.

Sign in / Sign up

Export Citation Format

Share Document